Title:
ANTIGENIC POLYPEPTIDE USABLE AS THERAPEUTIC AGENT FOR MALIGNANT NEOPLASM
Document Type and Number:
WIPO Patent Application WO/2008/053579
Kind Code:
A1
Abstract:
Disclosed are: a novel tumor antigen having an epitope for inducing a Th1 cell which is a CD4+ T cell specific to MAGE-A4; and use of the tumor antigen. Specifically disclosed is a polypeptide comprising an amino acid sequence selected from the following members a) to f) and having an activity of inducing the production of a cytokine in a Th cell specific to MAGE-A4: a) the amino acid sequence depicted in SEQ ID NO:1 or 2; b) an amino acid sequence having one to several tens of arbitrary amino acid residues added to the N-terminus and/or the C-terminus of the amino acid sequence of item a); c) an amino acid sequence having 1 to 5 amino acid residues deleted at the N-terminus and/or the C-terminus of the amino acid sequence of item a); d) an amino acid sequence having one to several amino acid residues substituted and/or deleted in the amino acid sequence of item a); e) an amino acid sequence having one to several tens of arbitrary amino acid residues added to the N-terminus and/or the C-terminus of an amino acid sequence which has one to several amino acid residues substituted and/or deleted in the amino acid sequence of item a); and f) an amino acid sequence having 1 to several amino acid residues substituted in an amino acid sequence having 1 to 5 amino acid residues deleted at the N-terminus and/or the C-terminus of the amino acid sequence of item a).
More Like This:
| WO/2000/063381 | MAMMALIAN PROTEIN WITH PUTATIVE FUNCTION IN SIGNAL TRANSDUCTION |
| WO/2022/038128 | N-TERMINAL CAPPING MODULES OF ANKYRIN REPEAT DOMAINS |
| JPH0795894 | PURIFICATION OF LIPOCORTIN |
Inventors:
NISHIMURA TAKASHI
Application Number:
PCT/JP2007/001073
Publication Date:
May 08, 2008
Filing Date:
October 02, 2007
Export Citation:
Assignee:
UNIV HOKKAIDO NAT UNIV CORP (JP)
NISHIMURA TAKASHI
NISHIMURA TAKASHI
International Classes:
C07K14/47; A61K35/12; A61K35/17; A61K39/00; A61P35/00; C07K16/18; C12N5/07; C12N5/0783; C12N5/0784; C12N5/09; C12N15/09; C12P21/08
Domestic Patent References:
| WO2002095051A2 | 2002-11-28 | |||
| WO2000078806A1 | 2000-12-28 | |||
| WO2000052045A2 | 2000-09-08 | |||
| WO1995019783A1 | 1995-07-27 | |||
| WO1997011669A2 | 1997-04-03 |
Foreign References:
| US9204354W | 1992-05-22 | |||
| US5342774A | 1994-08-30 | |||
| US5591430A | 1997-01-07 | |||
| US5965535A | 1999-10-12 | |||
| US9921230W | 1999-09-15 | |||
| JP2004123752A | 2004-04-22 |
Other References:
CHAUX P. ET AL.: "A MAGE-1 peptide recognized on HLA-DR15 by CD4(+) T cells", EUR. J. IMMUNOL., vol. 31, 2001, pages 1910 - 1916, XP009055210
ZHANG Y. ET AL.: "A MAG-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAG-3 protein", JOURNAL OF IMMUNOLOGY, vol. 171, no. 1, 2003, pages 219 - 225, XP002306158
CONSOGNO G. ET AL.: "Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3", BLOOD, vol. 101, no. 3, 2003, pages 1038 - 1044, XP003022702
WANG X.-F. ET AL.: "Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 56, 20 September 2006 (2006-09-20), pages 807 - 818, XP019514136
IMAI Y. ET AL.: "Sequence analysis of the MAGE gene family encoding human tumor-rejection antigens", GENE, vol. 160, 1995, pages 287 - 290, XP004042161
NIELSEN M. ET AL.: "Improved prediction of MHC class I and Class II epitopes using a novel Gibbs sampling approach", BIOINFORMATICS, vol. 20, no. 9, 2004, pages 1388 - 1397, XP003022703
ZHANG G.L. ET AL.: "MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides", NUCLEIC ACIDS RESEARCH, vol. 33, 2005, pages W172 - W179, XP003022704
SINGH H. AND RAGHAVA G.P.S.: "ProPred: prediction of HLA-DR binding sites", BIOINFORMATICS, vol. 17, no. 12, 2001, pages 1236 - 1237, XP002371461
ZHANG YUE ET AL.: "The cellular and molecular mechanisms underlying Th1 cell adjuvant therapy for tumor", DAI 10 KAI SOCIETY FOR FUNDAMENTAL CANCER IMMUNOLOGY SOKAI SHOROKU, 30 June 2006 (2006-06-30), pages 43, XP003022705
TOPALIAN, S. L. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 9461 - 9465
PLAEN ET AL., IMMUNOGENETICS, vol. 40, 1994, pages 360 - 369
TRAVERSARI ET AL., IMMUNOGENETICS, vol. 35, 1992, pages 145
VAN DER BRUGGEN ET AL., SCIENCE, vol. 254, 1991, pages 1643
DUFFOUR M. T. ET AL., EUR. J. IMMUNOL., vol. 29, 1999, pages 3329 - 3337
YOSHIHIRO M. ET AL., CLIN. CANCER RES., vol. 121, 2005, pages 5581 - 5589
TIM ET AL., IMMUNOLOGY TODAY, vol. 17, no. 3, 1996, pages 138 - 146
NISHIMURA ET AL., J. EXP. MED., vol. 190, no. 5, 1999, pages 617 - 627
SABURO AIMOTO ET AL.: "Yukikagobutsu-no-Gosei", THE CHEMICAL SOCIETY OF JAPAN, article "Jikken Kagaku Koza"
See also references of EP 2090585A4
ZHANG Y. ET AL.: "A MAG-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAG-3 protein", JOURNAL OF IMMUNOLOGY, vol. 171, no. 1, 2003, pages 219 - 225, XP002306158
CONSOGNO G. ET AL.: "Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3", BLOOD, vol. 101, no. 3, 2003, pages 1038 - 1044, XP003022702
WANG X.-F. ET AL.: "Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family", CANCER IMMUNOLOGY IMMUNOTHERAPY, vol. 56, 20 September 2006 (2006-09-20), pages 807 - 818, XP019514136
IMAI Y. ET AL.: "Sequence analysis of the MAGE gene family encoding human tumor-rejection antigens", GENE, vol. 160, 1995, pages 287 - 290, XP004042161
NIELSEN M. ET AL.: "Improved prediction of MHC class I and Class II epitopes using a novel Gibbs sampling approach", BIOINFORMATICS, vol. 20, no. 9, 2004, pages 1388 - 1397, XP003022703
ZHANG G.L. ET AL.: "MULTIPRED: a computational system for prediction of promiscuous HLA binding peptides", NUCLEIC ACIDS RESEARCH, vol. 33, 2005, pages W172 - W179, XP003022704
SINGH H. AND RAGHAVA G.P.S.: "ProPred: prediction of HLA-DR binding sites", BIOINFORMATICS, vol. 17, no. 12, 2001, pages 1236 - 1237, XP002371461
ZHANG YUE ET AL.: "The cellular and molecular mechanisms underlying Th1 cell adjuvant therapy for tumor", DAI 10 KAI SOCIETY FOR FUNDAMENTAL CANCER IMMUNOLOGY SOKAI SHOROKU, 30 June 2006 (2006-06-30), pages 43, XP003022705
TOPALIAN, S. L. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 9461 - 9465
PLAEN ET AL., IMMUNOGENETICS, vol. 40, 1994, pages 360 - 369
TRAVERSARI ET AL., IMMUNOGENETICS, vol. 35, 1992, pages 145
VAN DER BRUGGEN ET AL., SCIENCE, vol. 254, 1991, pages 1643
DUFFOUR M. T. ET AL., EUR. J. IMMUNOL., vol. 29, 1999, pages 3329 - 3337
YOSHIHIRO M. ET AL., CLIN. CANCER RES., vol. 121, 2005, pages 5581 - 5589
TIM ET AL., IMMUNOLOGY TODAY, vol. 17, no. 3, 1996, pages 138 - 146
NISHIMURA ET AL., J. EXP. MED., vol. 190, no. 5, 1999, pages 617 - 627
SABURO AIMOTO ET AL.: "Yukikagobutsu-no-Gosei", THE CHEMICAL SOCIETY OF JAPAN, article "Jikken Kagaku Koza"
See also references of EP 2090585A4
Attorney, Agent or Firm:
SAEKI, Norio et al. (Aminosan Kaikan Building15-8, Nihonbashi 3-chom, Chuo-ku Tokyo 27, JP)
Download PDF:
Previous Patent: USER GROUPING APPARATUS AND USER GROUPING METHOD
Next Patent: RETICULAR HEATER FOR STEERING WHEEL
Next Patent: RETICULAR HEATER FOR STEERING WHEEL